Physician profile
Brian C Gartrell
NPI 1225262538
$981.01
in general payments reported to CMS, 2019-2025
19 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $44.45 · 2022: $134 · 2023: $165 · 2024: $105 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $210.68 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $184.55 | 2022-2025 | |
| Novo Nordisk INC | $137.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $75.74 | 2019 | |
| Allergan, INC. | $58.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $51.87 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.33 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $32.97 | 2023-2024 | Shingrix |
| Mylan Specialty L.P. | $31.18 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.12 | 2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $21.85 | 2025 | |
| Lilly USA, LLC | $16.93 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $15.19 | 2019 | |
| Pfizer INC. | $15.01 | 2023 | |
| Upsher-Smith Laboratories LLC | $14.98 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.78 | 2024 | Xifaxan |
| Amarin Pharma, INC. | $14.60 | 2019 | |
| Acadia Pharmaceuticals INC | $13.05 | 2022 | |
| Sanofi Pasteur INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gartrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.